MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Abstract Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are TP53 wild-type; t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sarah E. Woodfield, Yan Shi, Roma H. Patel, Zhenghu Chen, Aayushi P. Shah, Richard S. Whitlock, Aryana M. Ibarra, Samuel R. Larson, Stephen F. Sarabia, Andrew Badachhape, Zbigniew Starosolski, Ketan B. Ghaghada, Pavel Sumazin, D. Allen Annis, Dolores López-Terrada, Sanjeev A. Vasudevan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/2c835b5e701047a99457ad48818f16a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2c835b5e701047a99457ad48818f16a6

Ejemplares similares